This article reviews the unique toxicities and adverse effects of blinatumomab and inotuzumab ozogamicin and provide recommendations for prevention of adverse effects as well as the management options for each medication.
This article discusses the current management of this rare entity and provide an overview of the most relevant molecular findings, whilst illustrating the potential value that prescreening panels can offer, searching for actionable targets (MSI/dMMR, PD-L1, BRAFv600E) to guide therapy with promising agents that could fill a void in this disease.
This article discusses the role of mAbs in follicular lymphoma and marginal zone lymphoma along with reviewing the current data about the use of biosimilar mAbs in these diseases.
This article summarizes the current status and ongoing clinical trials incorporating immunotherapy into the management of inoperable stage III nonsmall cell lung cancer.
This review discusses the evidence on second-line options for hepatocellular carcinoma, focusing on the latest results that are currently refining the treatment scenario.
